Kongresový poster

Time to subsequent therapy in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus carboplatin-paclitaxel compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

ZOBRAZIT